WIREDUP: Wearable Insoles for Recurrent Diabetic Ulcer Prevention

Sponsor

Orpyx Medical Technologies Inc. (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT05950659

Collaborator

(none)

500

Enrollment

Arms

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The primary aim of this study is to demonstrate the impact of the Orpyx® SI Sensory Insoles (Orpyx Medical Technologies Inc., Calgary AB, Canada) ("Orpyx" or "the Company") as an adjunct to the standard of care (SOC), as compared to SOC alone, on reducing plantar ulceration incidence in individuals who are at risk for developing diabetic foot complications.

The secondary aims of this study are to evaluate participant quality of life, participant engagement, and economic impact, including cost-effectiveness and cost-utility. The study will also use the unique data set collected (plantar pressure, temperature, step count, movement and adherence feedback) to identify foot-loading histories that either lead to or prevent the development of ulceration in the diabetic foot.

Condition or Disease	Intervention/Treatment	Phase
Diabetes Peripheral Neuropathy Diabetic Foot Diabetic Foot Ulcer	Device: Orpyx SI Sensory Insole System	N/A

Study Design

Study Type:

Interventional

Anticipated Enrollment :

500 participants

Allocation:

Randomized

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Prevention

Official Title:

Prevention of Foot Ulcer Recurrence in Individuals Who Are at High-risk for Diabetic Foot Complications Using the Orpyx SI Sensory Insole System: a Multisite, Randomized, Controlled Trial

Anticipated Study Start Date :

Jan 1, 2024

Anticipated Primary Completion Date :

Jan 1, 2027

Anticipated Study Completion Date :

Jun 1, 2027

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Intervention	Device: Orpyx SI Sensory Insole System The Orpyx SI Sensory Insoles System uses Orpyx Sensory Technology: a powered limb overload warning technology intended for monitoring physiologic parameters, such as plantar pressure, temperature, motion, and adherence, and providing real-time cues for pressure offloading
No Intervention: Control

Arm

Intervention/Treatment

Experimental: Intervention

Device: Orpyx SI Sensory Insole System

The Orpyx SI Sensory Insoles System uses Orpyx Sensory Technology: a powered limb overload warning technology intended for monitoring physiologic parameters, such as plantar pressure, temperature, motion, and adherence, and providing real-time cues for pressure offloading

No Intervention: Control

Outcome Measures

Primary Outcome Measures

Plantar ulcer recurrence [12 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Diagnosed Type 1 or 2 diabetes
Clinically diagnosed neuropathy via Neuropathy Monofilament Test
Qualification as a "high-risk participant," meaning a recent history (<12 months) of a healed diabetic neuropathic ulceration on the weight-bearing surface of one or both feet (this includes the plantar distal toe surface)
Complete healing of any previous foot ulcers, as defined by complete re-epithelialization of that ulcer which is confirmed by two medical exams that occur at least two weeks apart (V0 and V1)
Ability to walk independently (without use of wheelchair) for 30 steps. Use of a walker or cane is acceptable as long as the participant can walk for at least 30 steps.
Aged >18 years
Ability to understand all study requirements and have a life expectancy greater than the study duration
Vascular assessment (i.e., ABI, segmental pressure) that demonstrates the participant has adequate lower extremity perfusion
Subject is willing and able to maintain the required offloading (as applicable for the location of the healed ulcer)
Subject is willing and able to wear the Orpyx Sensory Insoles during ambulatory activity and at home during waking hours, and for a minimum of 5 hours per day
Compatibility of the device with the participant's footwear
Most recent HbA1c level of < 12.0% (in the last 12 months)
Amputations, if present, are compatible with the use of insoles

Exclusion Criteria:

Active ulcer or presence of other open chronic wound (on foot or other body surface), regardless of etiology (e.g., vasculitis, neoplasms, or hematological disorders)
History of known non-neuropathic foot ulcer (e.g., arterial, or venous insufficiency ulcer)
Presence of severe vascular disease (refer to acceptable ABI parameters in inclusion criteria)
Dementia
Psychiatric illness or social situations that would limit compliance with the study
Serious underlying balance dysfunction, regardless of etiology
Significant cardiopulmonary or other systemic disease limiting the participant's ability to walk at least 30 steps or to stand for an amount of time equal to or greater than five (5) minutes
Current participation in another clinical investigation of a medical device or a drug; or participation in such a study within 30 days prior to study enrolment
Osteomyelitis or gangrene of the lower extremity
Uncorrected plantar Charcot neuroarthropathy
Bunion which would predispose ulcer formation (clinician discretion)
Extreme equinus
Hallux valgus
Hallux rigidus / limitus
HbA1c levels >= 12%
At the start of V1, and prior to randomization, the subject no longer meets the entrance criteria (inclusion and exclusion)
Any condition that would affect or limit the ability to properly fit both shoes with the device under study
Subject has a history of intercurrent illness or conditions that would compromise the safety of the subject or their ability to participate in the study
Amputations on the foot which the clinician deems incompatible with the insoles (i.e., those that require additive insole modifications)